Study on Trastuzumab Deruxtecan and Nivolumab for Patients Free of Disease After Treatment for HER-2 Positive Esophageal and Gastroesophageal Cancers | Clinical Trial

Study on Trastuzumab Deruxtecan and Nivolumab for Patients Free of Disease After Treatment for HER-2 Positive Esophageal and Gastroesophageal Cancers | Clinical Trial | Right2Hope